Guardant Health, Inc. (GH)

NMS – Real Time Price. Currency in USD

149.22

+6.28 (4.39%)

At close: Jun 26, 2026, 4:00 PM EDT

151.00

+1.78 (1.19%)

After-hours: Jun 26, 2026, 7:44 PM EDT

12.06.2026

Gamehost Shareholders Approve Sale to Pure Casino Entertainment

Red Deer, Alberta--(Newsfile Corp. - June 12, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that its shareholders (the "Gamehost Shareholders") have approved its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction"). The Transaction was approved at a special meeting of the Gamehost Shareholders held on June 11, 2026 (the "Meeting").

11.06.2026

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) for Boehringer Ingelheim's HERNEXEOS® (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option. The approval enables Guardant360 CDx, a liquid biopsy test tha.

04.06.2026

Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favorite

This biotech has a one-of-a-kind colon cancer blood test. Shares broke out of a base on recent news.

28.05.2026

Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026. Key data that will be prese.

27.05.2026

Baron Health Care Fund Q1 2026 Portfolio Activity

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.

27.05.2026

Guardant Health Is Poised To Break Out At The Open — Here's Why It Surged

Guardant Health stock spiked Wednesday after the American Cancer Society recommended its blood test as a screening tool for colon cancer.

27.05.2026

American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield as a choice for patients who decline or have not completed stool-based or visual examination screening tests. In an effort to address persistent screening gaps and.

Videos

13.02.2026

Neutral

Analyzing Profit Zones For Walmart, Quanta Services And Guardant Health Ahead Of Earnings | IBD

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
GH	Goldman	Buy	undefined >> $165	June 5th 2026

Press releases

12.06.2026

Gamehost Shareholders Approve Sale to Pure Casino Entertainment

11.06.2026

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®

27.05.2026

American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

20.05.2026

FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights and helping clinicians make better-informed treatment selection decisions for patients with advanced cancer. Guardant360 Liquid CDx is the largest FDA-approved liquid biopsy panel, assess.

Guardant Health, Inc. (GH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Guardant Health, Inc. (GH)

Gamehost Shareholders Approve Sale to Pure Casino Entertainment

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®

Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favorite

Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting

Baron Health Care Fund Q1 2026 Portfolio Activity

Guardant Health Is Poised To Break Out At The Open — Here's Why It Surged

American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

Videos

Upgrades / Downgrades

Press releases

Gamehost Shareholders Approve Sale to Pure Casino Entertainment

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®

American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint

Gamehost Shareholders Approve Sale to Pure Casino Entertainment

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®

Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favorite

Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting

Baron Health Care Fund Q1 2026 Portfolio Activity

Guardant Health Is Poised To Break Out At The Open — Here's Why It Surged

American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

Videos

Upgrades / Downgrades

Press releases

Gamehost Shareholders Approve Sale to Pure Casino Entertainment

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®

American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint

Search stocks

Guardant Health, Inc. (GH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Guardant Health, Inc. (GH)

Gamehost Shareholders Approve Sale to Pure Casino Entertainment

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®

Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favorite

Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting

Baron Health Care Fund Q1 2026 Portfolio Activity

Guardant Health Is Poised To Break Out At The Open — Here's Why It Surged

American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

Videos

Upgrades / Downgrades

Press releases

Gamehost Shareholders Approve Sale to Pure Casino Entertainment

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®

American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint

Gamehost Shareholders Approve Sale to Pure Casino Entertainment

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®

Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favorite

Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting

Baron Health Care Fund Q1 2026 Portfolio Activity

Guardant Health Is Poised To Break Out At The Open — Here's Why It Surged

American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

Videos

Upgrades / Downgrades

Press releases

Gamehost Shareholders Approve Sale to Pure Casino Entertainment

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®

American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint